Advanced search
Publication Cover
Leukemia & Lymphoma Volume 61, 2020 - Issue 12
Submit an article Journal homepage
5,817
Views
11
CrossRef citations to date
0
Altmetric
Original Articles

Primary prophylaxis with G-CSF may improve outcomes in patients with newly diagnosed stage III/IV Hodgkin lymphoma treated with brentuximab vedotin plus chemotherapy

David Strausa Memorial Sloan Kettering Cancer Center, New York City, NY, USACorrespondence[email protected]
View further author information
,
Graham Collinsb Oxford Cancer and Hematology Center, Churchill Hospital, Oxford, UKView further author information
,
Jan Walewskic Maria Sklodowska-Curie Memorial Institute and Oncology Center, Warsaw, PolandView further author information
,
Pier Luigi Zinzanid Institute of Hematology Seragnoli, University of Bologna, Bologna, ItalyView further author information
,
Andrew Grigge Department of Clinical Haematology, Austin Hospital, Melbourne, AustraliaView further author information
,
Anna Suredaf Institut Català d'Oncologia-Hospitalet, Hospital Quirón Dexeus, Barcelona, SpainView further author information
,
Arpad Illesg University of Debrecen, Faculty of Medicine, Debrecen, HungaryView further author information
,
Tae Min Kimh Seoul National University Hospital, Seoul, Republic of KoreaView further author information
,
Sergey Alekseevi Petrov Research Institute of Oncology, St. Petersburg, RussiaView further author information
,
Lena Spechtj Department of Oncology, Rigshospitalet, University of Copenhagen, Copenhagen, DenmarkView further author information
,
Valeria Buccherik Hematology Service, Hospital das Clinicas HCFMUSP, Faculty of Medicine, University of São Paulo, São Paulo, BrazilView further author information
,
Anas Younesa Memorial Sloan Kettering Cancer Center, New York City, NY, USAView further author information
,
Joseph Connorsl BC Cancer Centre for Lymphoid Cancer, Vancouver, CanadaView further author information
,
Andres Forero-Torresm Seattle Genetics, Bothell, WA, USAView further author information
,
Keenan Fentonm Seattle Genetics, Bothell, WA, USAView further author information
,
Ashish Gautamn Millennium Pharmaceuticals, Cambridge, MA, USAView further author information
,
Indra Purevjaln Millennium Pharmaceuticals, Cambridge, MA, USAView further author information
,
Rachael Liun Millennium Pharmaceuticals, Cambridge, MA, USAORCID Iconhttps://orcid.org/0000-0001-6033-4510View further author information
ORCID Icon &
Andrea Gallaminio Research and Clinical Innovation, Antoine-Lacassagne Cancer Center, Nice, FranceView further author information
 show all
Pages 2931-2938 | Received 06 Mar 2020, Accepted 29 Jun 2020, Published online: 25 Aug 2020

Citations (11)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Burhan Ferhanoglu & Murat Ozbalak. (2023) Sequencing novel agents in the treatment of classical Hodgkin lymphoma. Expert Review of Hematology 0:0, pages 1-25.
Read now

Articles from other publishers (10)

Moonho Kim, Yongchel Ahn, Heui-June Ahn, Suk-Hun Ha, Ho-Suk Oh, Jae-Seok Song, Woong-Sub Park & Sang-Wook Yi. (2023) Impact of primary prophylaxis by pegfilgrastim in diffuse large B-cell lymphoma treated with R-CHOP. Annals of Hematology.
Crossref
Shobana Anpalakhan, Prerana Huddar, Roya Behrouzi, Alessio Signori, Judith Cave, Charles Comins, Alessio Cortellini, Alfredo Addeo, Carles Escriu, Hayley McKenzie, Gloria Barone, Lisa Murray, Gagan Bhatnagar, David J. Pinato, Christian Ottensmeier, Fabio Gomes & Giuseppe Luigi Banna. (2023) The Effects of GCSF Primary Prophylaxis on Survival Outcomes and Toxicity in Patients with Advanced Non-Small Cell Lung Cancer on First-Line Chemoimmunotherapy: A Sub-Analysis of the Spinnaker Study. International Journal of Molecular Sciences 24:2, pages 1746.
Crossref
H. Miles Prince, Martin Hutchings, Eva Domingo-Domenech, Dennis A. Eichenauer & Ranjana Advani. (2022) Anti-CD30 antibody–drug conjugate therapy in lymphoma: current knowledge, remaining controversies, and future perspectives. Annals of Hematology 102:1, pages 13-29.
Crossref
Swetha Kambhampati & Alex F. Herrera. (2022) Incorporating novel agents into frontline treatment of Hodgkin lymphoma. Hematology 2022:1, pages 706-716.
Crossref
Shuang Xia, Yi-Chang Zhao, Lin Guo, Hui Gong, Yi-Kun Wang, Rui Ma, Bi-Kui Zhang, Yue Sheng, Mayur Sarangdhar, Yoshihiro Noguchi & Miao Yan. (2022) Do antibody–drug conjugates increase the risk of sepsis in cancer patients? A pharmacovigilance study. Frontiers in Pharmacology 13.
Crossref
Stephen M. AnsellJohn RadfordJoseph M. ConnorsMonika Długosz-DaneckaWon-Seog KimAndrea GallaminiRadhakrishnan RamchandrenJonathan W. FriedbergRanjana AdvaniMartin HutchingsAndrew M. Evens, Piotr SmolewskiKerry J. SavageNancy L. BartlettHyeon-Seok EomJeremy S. AbramsonCassie DongFrank CampanaKeenan FentonMarkus PuhlmannDavid J. Straus. (2022) Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin’s Lymphoma. New England Journal of Medicine 387:4, pages 310-320.
Crossref
Abraham Avigdor, Fabrizio Trinchese, Francois Gavini, Nawal Bent‐Ennakhil, Mehul Dalal, Athanasios Zomas, Sharmeen Gettner Broun & Guido Gini. (2022) First‐line treatment of stage IIB to stage IV classical Hodgkin lymphoma in Italy, Israel, and Spain: Patient characteristics, treatment patterns, and clinical outcomes. eJHaem 3:2, pages 415-425.
Crossref
Andrew M. Evens, Joseph M. Connors, Anas Younes, Stephen M. Ansell, Won Seog Kim, John Radford, Tatyana Feldman, Joseph Tuscano, Kerry J. Savage, Yasuhiro Oki, Andrew Grigg, Christopher Pocock, Monika Dlugosz-Danecka, Keenan Fenton, Andres Forero-Torres, Rachael Liu, Hina Jolin, Ashish Gautam & Andrea Gallamini. (2021) Older patients (aged ≥60 years) with previously untreated advanced-stage classical Hodgkin lymphoma: a detailed analysis from the phase III ECHELON-1 study. Haematologica 107:5, pages 1086-1094.
Crossref
David J Straus, Monika Długosz-Danecka, Joseph M Connors, Sergey Alekseev, Árpád Illés, Marco Picardi, Ewa Lech-Maranda, Tatyana Feldman, Piotr Smolewski, Kerry J Savage, Nancy L Bartlett, Jan Walewski, Radhakrishnan Ramchandren, Pier Luigi Zinzani, Martin Hutchings, Javier Munoz, Hun Ju Lee, Won Seog Kim, Ranjana Advani, Stephen M Ansell, Anas Younes, Andrea Gallamini, Rachael Liu, Meredith Little, Keenan Fenton, Michelle Fanale & John Radford. (2021) Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial. The Lancet Haematology 8:6, pages e410-e421.
Crossref
Narendranath Epperla & Alex F. Herrera. (2021) How we incorporate novel agents into the treatment of classic Hodgkin lymphoma. Blood.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.